Annalisa Buniello,Daniel Suveges,Carlos Cruz-Castillo,Manuel Bernal Llinares,Helena Cornu,Irene Lopez,Kirill Tsukanov,Juan María Roldán-Romero,Chintan Mehta,Luca Fumis,Graham McNeill,James D Hayhurst,Ricardo Esteban Martinez Osorio,Ehsan Barkhordari,Javier Ferrer,Miguel Carmona,Prashant Uniyal,Maria J Falaguera,Polina Rusina,Ines Smit,Jeremy Schwartzentruber,Tobi Alegbe,Vivien W Ho,Daniel Considine,Xiangyu Ge,Szymon Szyszkowski,Yakov Tsepilov,Maya Ghoussaini,Ian Dunham,David G Hulcoop,Ellen M McDonagh,David Ochoa

Abstract:The Open Targets Platform (https://platform.opentargets.org) is a unique, open-source, publicly-available knowledge base providing data and tooling for systematic drug target identification, annotation, and prioritisation. Since our last report, we have expanded the scope of the Platform through a number of significant enhancements and data updates, with the aim to enable our users to formulate more flexible and impactful therapeutic hypotheses. In this context, we have completely revamped our target–disease associations page with more interactive facets and built-in functionalities to empower users with additional control over their experience using the Platform, and added a new Target Prioritisation view. This enables users to prioritise targets based upon clinical precedence, tractability, doability and safety attributes. We have also implemented a direction of effect assessment for eight sources of target–disease association evidence, showing the effect of genetic variation on the function of a target is associated with risk or protection for a trait to inform on potential mechanisms of modulation suitable for disease treatment. These enhancements and the introduction of new back and front-end technologies to support them have increased the impact and usability of our resource within the drug discovery community.

Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery